Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Emergency contraception

Essential points for quick revision.

Saved on this device
!
Every hour can preserve an option

Recent unprotected intercourse, sexual assault or method failure requires same-day assessment because oral and intrauterine options have finite windows.

Action: Record every exposure in the cycle, last normal period, current contraception and enzyme-inducing medicines; offer copper IUD first when eligible, provide oral EC immediately if chosen and complete the ongoing contraception and testing plan.

Synopsis

Select copper IUD, ulipristal or levonorgestrel emergency contraception by intercourse and ovulation timing, interactions, weight and the ongoing-method plan.

  • Offer a copper IUD to every eligible EC user because it is the most effective method, works after ovulation and can remain for continuing contraception.
  • Insert copper IUD within 120 hours of the first unprotected intercourse in the cycle or, when ovulation can be estimated, within five days after the earliest likely ovulation date.
  • Use ulipristal acetate 30mg within 120 hours or levonorgestrel 1.5mg within 72 hours. Oral EC delays ovulation and is ineffective after ovulation has occurred.

Key red flags

Pelvic pain, collapse, shoulder-tip pain or bleeding with a late period requires urgent ectopic-pregnancy assessment rather than routine EC alone.

A copper IUD is the most effective EC and can be inserted within 120 hours after first unprotected sex in the cycle or within five days of earliest estimated ovulation.

Levonorgestrel 1.5mg is recommended as soon as possible within 72 hours; ulipristal 30mg can be used up to 120 hours and is generally the more effective oral option later in the window.

During enzyme induction and for 28 days after stopping, offer copper IUD; if declined or unsuitable use LNG 3mg once with uncertainty counselling and do not use UPA.

After UPA wait five days before any progestogen-containing contraception; after LNG, ongoing hormonal contraception can start immediately.

Condom or method failure

Breakage, expulsion, delayed injection, missed pills or extended hormone-free interval require method-specific risk assessment.

Enzyme-inducer exposure

Current use or the 28 days after stopping changes oral EC choice and dose.

Possible established pregnancy

Late period, pregnancy symptoms, pain or bleeding requires testing and ectopic assessment; EC will not end a pregnancy.

Investigation priorities

01
Dated sexual and cycle historyFirst step

Identify the first and latest unprotected sex, cycle day and possible ovulation window.

Management branches

EC choice pathwayOffer copper before comparing tablets

Unprotected sex or method failure falls within an emergency-contraception window.

  1. Exclude urgent pregnancy symptoms, date every exposure, estimate earliest ovulation and identify current hormones and enzyme induction.
  2. Offer copper IUD as most effective within 120 hours of first exposure or five days after earliest estimated ovulation.

Key medicines

Ulipristal acetate emergency contraceptionTake 30mg orally once as soon as possible and within 120 hours of unprotected intercourse.Do not use with current or recent enzyme induction; recent progestogen may reduce effect, wait five days before restarting hormones, and do not double the dose.
Levonorgestrel emergency contraceptionTake 1.5mg orally once as soon as possible and within 72 hours; use 3mg once when an enzyme inducer is current or was stopped within 28 days and copper IUD is declined.Effectiveness falls with delay and after ovulation; higher weight and induction may reduce effect, so offer copper IUD and arrange follow-up testing.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom